



WHAT IS CLAIMED IS:

1. A compound of the formula:



wherein X is a linker group having 2-5 functional groups or is absent, n = 1, and Formula II is



wherein R, A, B, C, D, E, F, G, H, I, J, and K are selected from the following or may be absent, and wherein K is Arg or an Arg derivative:

R	A	B	C	D	E	F	G	H	I	J	K
-1	0	1	2	3	4	5	6	7	8	9	
Absent or 3,3DP Aaa Ac	Absent or DmK Lys Lys(eF lu)	Absent or Apc Arg DArg	Absent or ApC Arg DmK	Absent or MeP Nig NMF	Absent or Hyp Pro	Absent or Ava BAla Dpr	Absent or Add Aud CpG	Absent or Arg Gly Pac	Absent or 2Nal DCpG DF5F	Absent or 2Nal 2Nal-NH ₂	Absent or Arg(H) Arg-CH ₂ O H Arg-NH ₂ Arg(N O ₂) Arg-OMe DArg DArg-NH ₂ DArg(NO ₂)
Aca	NiK	DLys	NiK	Pro		Eac	DDM F	Pac	DIgl	3,4F2 F	Arg-NH ₂
BApp	PzO	DmK	NiO			Gly	DMF	Sei	DPFF	3Pal	Arg(N O ₂)
Cca		DniK	PaF				Eac	Thr	DPhe	Ac6c	Arg-OMe
Cin		DpaF	PzO				Igl		DTic	Aic	DArg
Dca		DPzK					Lys		Gly	Ana	DArg-NH ₂
Dcg		DPzO					Pac		mABz	Apb	DArg(NO ₂)
Dhq		Lys					Phe		pABz	Apb	
Dmac		NiK					Thi.		Pac	Atpc	
Dpa		PaF							PaF(D cg)	Bip	
F5bz		PzO							pAmb	Cmp	
F5c		DArg- (NO ₂)	Arg- (NO ₂)							CpG	
F5pa											
Gun										DhPhe	
Hxa										Dpr(F bz)	
Mca										Dpr(Pa a)	
Mcg										F5F	
										F5F-NH ₂	

10035662-122801


Moti
Pcc
Ppa
Pya

Saa
Ste


Tfmc

Hphe
Ica
Igl
Igl-
NH₂
Ileu
Lys(C
H₃)₃
Lys(F
5bz)
Mapa
MBC
MFF
Nc6G
Nc7G
NMF
OBS
OBT
OBY
OC2Y
Oic
Oic-
NH₂
PABz
Pac
PaF(F
5c)
PaF(F
bz)
PaF(M
cg)
PaF(P
pa)
PaF(Si
n)
pAmb
pAPa
PCF
PdF
PFF
PFF-
NH₂
Phe
PNF
Thi
Tic
Trp
Trx
Tyr

2. A compound of the formula:



wherein X is a linker group having 2-5 functional groups or is absent, n = 1, and Formula III is



wherein R, A, B, C, D, E, and F are selected from the following or may be absent, and wherein F is not Arg or an Arg derivative:

R	A	B	C	D	E	F
1	2	3	4	5	6	
Absent or	Absent or	Absent or	Absent or	Absent or	Absent or	Absent or
2,2Dp	DArg	Arg	Add	or	1Nal	2Nal
3,3Dp	DArg(NO ₂)		Aud	2Nal	2Nal	3Pal
)			3Pal		
Aaa			Ava	Arg	2Nap	ABza
Ac			Eac	Arg(Tos)	3Pal	ABza
Aca			Lys	Atcp	Apa	Ama
Boc			Pac	D2Nal	Arg	Ampy
Chc				DArg	Arg-NH ₂	Ampz
Cin				DArg(Tos)	Asp	Apa
				s)		
Ctim				DF5F	Atc	Api
Dca				Digl	Atcp	Aptp
Dcg				DPFF	Bip	Aqd
Dhq				Eac	BtA	Aqu
Dmac				F5F	Cys(Meb)	Arg(H)
Dns				Gly	Cys(SO3H)	Arg-CH ₂ OH
						Arg-NH ₂
Dpa				His	D2Nal	Arg-OMe
F5c				Igl	DArg	Asp
F5pa				mABz	DArg-NH ₂	Asp(Aqu)
F5po				OC2Y	F5F	Atcp
Gbc				Pac	Glu	Atmp
Gun				PFF	Gly	AtmpO
Hxa					Igl	Atpm
Meg					Inp	Cyh
Mse					Iqa	Dmab
Pya					mABz	Dmm
Seb					MC2Y	Dmp
Sin					N-Dmb-	
					Tyr(Bz)-	
					OMe	
Sul					OC2Y	Dpea

1035652-127001



- 1035652-127001

1035652-127001


1035652-127001

1035652-127001


1035652-127001

1035652-127001

4. A compound of the formula:




wherein X is a linker group having 2-5 functional groups or is absent; n = 1; c indicates cyclization, the site of cyclization selected from the group consisting of the c-terminus, and a side chain functional group; and Formula V is



wherein X, A, B, C, D, E, F, G, H, I, J, and K are selected from the following or may be absent:

X	A	B	C	D	E	F	G	H	I	J	K
	-1	0	1	2	3	4	5	6	7	8	9
Absent or α-Aca 3,3Dp	Absent or Ava BALA DmK Glt Lys Suc	Absent or DArg DNik DPaF DPzK DPzO	Absent or Arg NiK PzO	Absent or Pro	Absent or Hyp	Absent or Gly	Absent or Add Aud Ava BALA DNMF Eac Igl Thi	Absent or DArg Ser Thr	Absent or DDab DDpr DF5F DIgl DLys DOm DPaF Nig Pac Phe	Absent or DTrp F5F Lys Nc7G Oic PaF PFF Phe	Absent or Arg Leu NiK PaF 3Pal

5. A compound of the formula



wherein [ACA] is a compound of claim 1, 2, 3, or 4.

6. A method to inhibit tumor growth in an animal in need of such inhibition, comprising administering a compound selected from the group consisting of a compound of claim 1, DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg, DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Nig-Arg, DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Oic-Arg, Lys-Lys-Arg-Pro-Hyp-Gly-Igl-Ser-DTic-ChG, DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Nc7G-Arg, and DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Oic-Arg.

7. A method to inhibit tumor growth in an animal in need of such inhibition, comprising administering a compound selected from the group consisting of a compound of claim 2, DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg, DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Nig-Arg, DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Oic-Arg, Lys-Lys-Arg-Pro-Hyp-Gly-Igl-Ser-DTic-ChG, DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Nc7G-Arg, and DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Oic-Arg.
8. A method to inhibit tumor growth in an animal in need of such inhibition, comprising administering a compound selected from the group consisting of a compound of claim 3, DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg, DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Nig-Arg, DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Oic-Arg, Lys-Lys-Arg-Pro-Hyp-Gly-Igl-Ser-DTic-ChG, DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Nc7G-Arg, and DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Oic-Arg.
9. A method to inhibit tumor growth in an animal in need of such inhibition, comprising administering a compound selected from the group consisting of a compound of claim 4, DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg, DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Nig-Arg, DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Oic-Arg, Lys-Lys-Arg-Pro-Hyp-Gly-Igl-Ser-DTic-ChG, DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Nc7G-Arg, and DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Oic-Arg.
10. A method to inhibit tumor growth in an animal in need of such inhibition, comprising administering a compound selected from the group consisting of a compound of claim 5, DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg, DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Nig-Arg, DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Oic-Arg, Lys-Lys-Arg-Pro-Hyp-Gly-Igl-Ser-DTic-ChG, DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Nc7G-Arg, and DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Oic-Arg.
11. A method to induce apoptosis, comprising administering a compound selected from the group consisting of a compound of claim 1, DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg, DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Nig-Arg, DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Oic-Arg,

Lys-Lys-Arg-Pro-Hyp-Gly-Igl-Ser-DTic-ChG,
DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Nc7G-Arg, and
DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Oic-Arg.

12. A method to induce apoptosis, comprising administering a compound selected from the group consisting of a compound of claim 2,
DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg,
DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Nig-Arg,
DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Oic-Arg,
Lys-Lys-Arg-Pro-Hyp-Gly-Igl-Ser-DTic-ChG,
DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Nc7G-Arg, and
DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Oic-Arg.

13. A method to induce apoptosis, comprising administering a compound selected from the group consisting of a compound of claim 3,
DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg,
DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Nig-Arg,
DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Oic-Arg,
Lys-Lys-Arg-Pro-Hyp-Gly-Igl-Ser-DTic-ChG,
DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Nc7G-Arg, and
DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Oic-Arg.

14. A method to induce apoptosis, comprising administering a compound selected from the group consisting of a compound of claim 4,
DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg,
DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Nig-Arg,
DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Oic-Arg,
Lys-Lys-Arg-Pro-Hyp-Gly-Igl-Ser-DTic-ChG,
DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Nc7G-Arg, and
DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Oic-Arg.

15. A method to induce apoptosis, comprising administering a compound selected from the group consisting of a compound of claim 5,
DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg,
DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Nig-Arg,
DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Oic-Arg,
Lys-Lys-Arg-Pro-Hyp-Gly-Igl-Ser-DTic-ChG,
DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Nc7G-Arg, and
DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Oic-Arg.